AUTHOR=Li Chaoping , Li Zhaoming , Zhang Mingzhi 

TITLE=Low Expression of 14-3-3beta Is Associated With Adverse Survival of Diffuse Large B-Cell Lymphoma Patients

JOURNAL=Frontiers in Medicine

VOLUME=6

YEAR=2019

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2019.00237

DOI=10.3389/fmed.2019.00237

ISSN=2296-858X

ABSTRACT=<p>Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma in the world, is highly heterogeneous. Although current therapies have improved the clinical outcome, 30–40% of the patients are still not cured. Thus, novel treatment options such as targeted therapy is urgently needed. Accumulating evidence suggests that 14-3-3beta protein plays an important role in tumorigenesis and tumor progression. However, the specific roles of 14-3-3beta in DLBCL are still poorly understood. In this study, we retrospectively analyzed 120 archived wax blocks obtained from patients with DLBCL (<italic>n</italic>  =  70) and non-neoplastic lymph nodes (<italic>n</italic>  =  50). Immunohistochemical staining showed that 14-3-3beta gene expression was significantly decreased in DLBCL tissues (<italic>P</italic> &lt; 0.001) compared to that in non-neoplastic lymph nodes. Low 14-3-3beta expression was significantly correlated with extra-nodal status (<italic>P</italic>  =  0.026), serum LDH level (<italic>P</italic>  =  0.023) and adverse survival of DLBCL patients. In survival analyses, low 14-3-3beta expression was significantly associated with adverse overall survival of the DLBCL patients (<italic>P</italic>  =  0.003). Using the Kaplan-Meier analysis module of the R2 microarray analysis and visualization platform (<ext-link ext-link-type="uri" xlink:href="http://r2.amc.nl" xmlns:xlink="http://www.w3.org/1999/xlink">http://r2.amc.nl</ext-link>), we also confirmed that low expression of 14-3-3beta gene had inferior overall survival in DLBCL patients. Based on our results, we conclude that low expression of 14-3-3beta is associated with adverse survival of diffuse large B-cell lymphoma patients, suggesting a novel prognostic marker and potential therapeutic target.</p>